NEW YORK (GenomeWeb News) – Cellectis Bioresearch today announced a collaboration with Axxam to offer integrated discovery services based on genomic engineering technologies.

According to Cellectis, a genome engineering firm, the collaboration will offer a one-stop shop approach to generating cell-based assays to the life science industry. Cellectis will use its genome engineering methods to modify genes of interest, and then Axxam will apply its expertise and technologies for cell line generation to develop functional cellular assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.